SG11201807834WA - Bridged bicyclic inhibitors of menin-mll and methods of use - Google Patents
Bridged bicyclic inhibitors of menin-mll and methods of useInfo
- Publication number
- SG11201807834WA SG11201807834WA SG11201807834WA SG11201807834WA SG11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA
- Authority
- SG
- Singapore
- Prior art keywords
- huron
- floor
- international
- ann arbor
- parkway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309362P | 2016-03-16 | 2016-03-16 | |
| US201662431387P | 2016-12-07 | 2016-12-07 | |
| PCT/US2017/022535 WO2017161002A1 (fr) | 2016-03-16 | 2017-03-15 | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807834WA true SG11201807834WA (en) | 2018-10-30 |
Family
ID=59851929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807834WA SG11201807834WA (en) | 2016-03-16 | 2017-03-15 | Bridged bicyclic inhibitors of menin-mll and methods of use |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10752639B2 (fr) |
| EP (1) | EP3429585B1 (fr) |
| JP (1) | JP7000333B2 (fr) |
| KR (1) | KR102419524B1 (fr) |
| CN (1) | CN109640987B (fr) |
| AU (1) | AU2017235462B2 (fr) |
| BR (1) | BR112018068702A2 (fr) |
| CA (1) | CA3015845A1 (fr) |
| HK (1) | HK1258821A1 (fr) |
| IL (1) | IL261625B (fr) |
| MA (1) | MA43823A (fr) |
| MX (1) | MX2018011092A (fr) |
| PH (1) | PH12018501955A1 (fr) |
| SG (1) | SG11201807834WA (fr) |
| TW (1) | TWI743096B (fr) |
| WO (1) | WO2017161002A1 (fr) |
| ZA (1) | ZA201805845B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (fr) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| EP4219449A3 (fr) | 2016-03-16 | 2023-10-11 | Kura Oncology, Inc. | Dérivés indoliques substitués et leurs procédés de préparation |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| MX2019002962A (es) | 2016-09-14 | 2019-07-04 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll. |
| BR112019004764A2 (pt) | 2016-09-14 | 2019-05-28 | Janssen Pharmaceutica Nv | inibidores bicíclicos fundidos da interação menina-mll |
| EP3555103B1 (fr) | 2016-12-15 | 2021-09-22 | Janssen Pharmaceutica NV | Dérivés d'azépane en tant qu'inhibiteurs de l'interaction ménine-mll |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| WO2018183857A1 (fr) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Pipéridines en tant qu'inhibiteurs covalents de la ménine |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (fr) * | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| WO2019189732A1 (fr) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | Dérivé d'amine secondaire cyclique réticulé optiquement actif |
| WO2020069027A1 (fr) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Traitement d'hémopathie maligne avec des inhibiteurs de ménine |
| CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
| EP3892278B1 (fr) | 2018-12-06 | 2024-02-28 | Daiichi Sankyo Company, Limited | Dérivé de cycloalcane-1,3-diamine |
| WO2020142559A1 (fr) * | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibiteurs de l'interaction ménine-mll |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| JP2023522166A (ja) * | 2020-04-07 | 2023-05-29 | シンダックス ファーマシューティカルズ， インコーポレイテッド | メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法 |
| BR112023023154A2 (pt) | 2021-05-08 | 2024-01-23 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334320A1 (fr) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Dérivés spiro substitués |
| WO2022241265A1 (fr) | 2021-05-14 | 2022-11-17 | Syndax Pharmaceuticals, Inc. | Inhibiteurs de l'interaction ménine-mll |
| EP4347588A1 (fr) | 2021-06-01 | 2024-04-10 | JANSSEN Pharmaceutica NV | Dérivés de phényl-1h-pyrrolo [2, 3-c] pyridine substitués |
| CA3218340A1 (fr) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines ou 1,2,4-triazines substituees par des amines spirocycliques |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer |
| WO2023220098A1 (fr) * | 2022-05-09 | 2023-11-16 | Syndax Pharmaceuticals, Inc. | Inhibiteurs de ménine-mll pour le traitement du cancer |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US510A (en) | 1837-12-07 | soeel | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US1007727A (en) | 1908-02-17 | 1911-11-07 | Oscar F Onken | Auxiliary table-top. |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
| JP3333870B2 (ja) | 1996-07-26 | 2002-10-15 | 国土交通省北陸地方整備局長 | 草刈機 |
| CA2264284A1 (fr) | 1996-08-23 | 1998-02-26 | Ralph P. Robinson | Derives de l'acide arylsulfonylamino hydroxamique |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| PT977733E (pt) | 1997-02-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acido arilsulfonilamino-hidroxamico |
| CA2279863A1 (fr) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices |
| AU722784B2 (en) | 1997-02-11 | 2000-08-10 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1382603B1 (fr) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant |
| WO2002088138A1 (fr) | 2001-04-30 | 2002-11-07 | Bayer Corporation | Nouveaux thiopheno[2,3-d]pyrimidines 4-amino-5,6-substitutes |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| NZ542236A (en) | 2003-03-31 | 2008-05-30 | Predix Pharmaceuticals Holding | New piperidinylamino-thieno[2,3-d]pyrimidine compounds |
| WO2005020897A2 (fr) | 2003-08-22 | 2005-03-10 | Dendreon Corporation | Compositions et methodes permettant de traiter une maladie associee a l'expression de trp-p8 |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| EP1768964A1 (fr) | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Modulateurs quinazoline d'activite de facteur de croissance hepatocyte/c-met permettant de traiter le cancer |
| WO2006132914A2 (fr) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Derives de cyclobutyl amine |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| MX2008003032A (es) | 2005-09-02 | 2008-03-24 | Tibotec Pharm Ltd | Benzodiazepinas como inhibidores del virus del la hepatitis c. |
| KR101359093B1 (ko) | 2005-09-19 | 2014-02-05 | 메르크 파텐트 게엠베하 | 시클로부테인 및 스피로［3.3］헵테인 화합물 |
| FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| RU2441869C2 (ru) | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
| WO2007115822A1 (fr) | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thiénopyrimidines ayant une activité inhibitrice mnk1/mnk2 utilisées dans des compositions pharmaceutiques |
| EP1903044A1 (fr) * | 2006-09-14 | 2008-03-26 | Novartis AG | Derivés de l'adénosine en tant qu' agonistes du récepteur A2A |
| WO2008070303A2 (fr) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Agents thérapeutiques permettant d'inhiber l'interaction mll-ménine pour traiter une leucémie |
| EP1947103A1 (fr) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, procédés de préparation correspondant et utilisation d'aryloxypropanolamines en tant que médicaments |
| WO2008099019A1 (fr) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazépinones utiles comme inhibiteurs du virus de l'hépatite c |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| DE602008004649D1 (de) | 2007-03-19 | 2011-03-03 | Council Scient Ind Res | Anthranilsäure-derivat als antikrebswirkstoff und verfahren zur herstellung davon |
| WO2008135232A1 (fr) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs |
| CA2687187A1 (fr) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibiteurs de mort cellulaire induite par la thapsigargine |
| WO2009017838A2 (fr) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
| WO2009064388A2 (fr) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibiteurs de la méthionine aminopeptidase humaine 1 et procédés de traitement de troubles |
| CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
| BRPI0912988A2 (pt) | 2008-05-22 | 2019-09-24 | Allergan Inc | compostos bicíclicos tendo atividade no receptor cxcr4. |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| CN102203067B (zh) | 2008-08-25 | 2014-01-15 | Irm责任有限公司 | Hedgehog通路调节剂 |
| US20100063047A1 (en) | 2008-09-10 | 2010-03-11 | Kalypsys, Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| AR077465A1 (es) | 2009-07-08 | 2011-08-31 | Leo Pharma As | Derivados de pirrolopirimidina como inhibidores de receptores jak y protein tirosin quinasas y uso farmaceutico de los mismos |
| EP2459533A4 (fr) | 2009-07-30 | 2013-01-16 | Univ Singapore | Inhibiteurs à petite molécule d'isoprénylcystéine carboxyl méthyltranférase avec une activité anticancer potentielle |
| EP2473054B1 (fr) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions et méthodes de traitement de la leucémie |
| CA2790613C (fr) | 2010-02-22 | 2018-01-02 | Merck Patent Gmbh | Hetarylaminonaphtyridines |
| KR101541086B1 (ko) | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| WO2013019966A1 (fr) * | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Dérivés bicycliques aromatiques utiles en tant que modulateurs du récepteur cxcr4 |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| CN103833759A (zh) * | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
| WO2014160478A1 (fr) | 2013-03-13 | 2014-10-02 | Flatley Discovery Lab | Composés et procédés pour le traitement de fibrose kystique |
| US9505781B2 (en) * | 2013-03-13 | 2016-11-29 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| ES2702951T3 (es) * | 2014-04-04 | 2019-03-06 | Syros Pharmaceuticals Inc | Inhibidores de quinasas dependientes de ciclina 7 (cdk7) |
| US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2016040330A1 (fr) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| JP2018538330A (ja) | 2015-12-22 | 2018-12-27 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 |
| EP3407884A4 (fr) | 2016-01-26 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | Inhibition de l'expression génique leucémogénique dans la leucémie mutantenpm1 |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| EP4219449A3 (fr) | 2016-03-16 | 2023-10-11 | Kura Oncology, Inc. | Dérivés indoliques substitués et leurs procédés de préparation |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (fr) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1 |
| CA3024180A1 (fr) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de l'interaction menine-mll |
| WO2018024602A1 (fr) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro [4,4] nonanes |
| BR112019004764A2 (pt) | 2016-09-14 | 2019-05-28 | Janssen Pharmaceutica Nv | inibidores bicíclicos fundidos da interação menina-mll |
| ES2948949T3 (es) | 2016-09-16 | 2023-09-22 | Vitae Pharmaceuticals Llc | Inhibidores de la interacción menina-MLL |
| EA201990699A1 (ru) | 2016-10-05 | 2019-09-30 | Янссен Фармацевтика Нв | Спиробициклические ингибиторы взаимодействия менин–mll |
-
2017
- 2017-03-15 CN CN201780030449.4A patent/CN109640987B/zh active Active
- 2017-03-15 MX MX2018011092A patent/MX2018011092A/es unknown
- 2017-03-15 JP JP2018544323A patent/JP7000333B2/ja active Active
- 2017-03-15 MA MA043823A patent/MA43823A/fr unknown
- 2017-03-15 TW TW106108619A patent/TWI743096B/zh active
- 2017-03-15 WO PCT/US2017/022535 patent/WO2017161002A1/fr active Application Filing
- 2017-03-15 EP EP17767444.7A patent/EP3429585B1/fr active Active
- 2017-03-15 US US16/082,645 patent/US10752639B2/en active Active
- 2017-03-15 KR KR1020187029700A patent/KR102419524B1/ko active IP Right Grant
- 2017-03-15 AU AU2017235462A patent/AU2017235462B2/en active Active
- 2017-03-15 CA CA3015845A patent/CA3015845A1/fr active Pending
- 2017-03-15 SG SG11201807834WA patent/SG11201807834WA/en unknown
- 2017-03-15 BR BR112018068702A patent/BR112018068702A2/pt not_active Application Discontinuation
-
2018
- 2018-08-30 ZA ZA2018/05845A patent/ZA201805845B/en unknown
- 2018-09-05 IL IL261625A patent/IL261625B/en unknown
- 2018-09-11 PH PH12018501955A patent/PH12018501955A1/en unknown
-
2019
- 2019-01-23 HK HK19101198.7A patent/HK1258821A1/zh unknown
-
2020
- 2020-07-13 US US16/927,844 patent/US11555041B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1258821A1 (zh) | 2019-11-22 |
| CN109640987A (zh) | 2019-04-16 |
| EP3429585A1 (fr) | 2019-01-23 |
| US20210107917A1 (en) | 2021-04-15 |
| US10752639B2 (en) | 2020-08-25 |
| MX2018011092A (es) | 2018-11-22 |
| US20190092783A1 (en) | 2019-03-28 |
| IL261625B (en) | 2021-08-31 |
| KR20180127406A (ko) | 2018-11-28 |
| IL261625A (en) | 2018-10-31 |
| AU2017235462A1 (en) | 2018-09-27 |
| CA3015845A1 (fr) | 2017-09-21 |
| BR112018068702A2 (pt) | 2019-01-15 |
| JP7000333B2 (ja) | 2022-02-10 |
| EP3429585B1 (fr) | 2021-11-24 |
| CN109640987B (zh) | 2022-12-02 |
| KR102419524B1 (ko) | 2022-07-08 |
| US11555041B2 (en) | 2023-01-17 |
| WO2017161002A1 (fr) | 2017-09-21 |
| TW201742870A (zh) | 2017-12-16 |
| ZA201805845B (en) | 2023-03-29 |
| JP2019508426A (ja) | 2019-03-28 |
| PH12018501955A1 (en) | 2019-06-17 |
| TWI743096B (zh) | 2021-10-21 |
| EP3429585A4 (fr) | 2019-10-09 |
| AU2017235462B2 (en) | 2021-07-01 |
| MA43823A (fr) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807834WA (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201806282XA (en) | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers |